Notice concerning Completion of Disposal of Treasury Shares as Tenure-based Restricted Stock Compensation and Performance-linked Restricted Stock Compensation
Osaka, Japan, July 18, 2025 - Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “the Company”) today announced that the payment procedures were completed on July 18, 2025 as follows for disposal of treasury shares as tenure-based restricted stock compensation and performance-linked restricted stock compensation resolved at the Board of Directors meeting held on June 19, 2025. For more details, please refer to “Notice of Disposal of Treasury Shares as Tenure-based Restricted Stock Compensation and Performance-linked Restricted Stock Compensation” dated June 19, 2025.
Overview of Disposal of Treasury Shares
1. Disposal as tenure-based restricted stock compensation
| (1) Disposal date | July 18, 2025 |
| (2) Class and number of shares to be disposed of | 29,200 shares of common stock of the Company |
| (3) Disposal price | 1,579 yen per share |
| (4) Total value of shares to be disposed of | 46,106,800 yen |
| (5) Allottees and number thereof; number of disposed shares | Board of Directors of the Company (excluding Outside Directors): 3 persons / 29,200 shares |
2. Disposal as performance-linked restricted stock compensation
| (1) Disposal date | July 18, 2025 |
| (2) Class and number of shares to be disposed of | 105,800 shares of common stock of the Company |
| (3) Disposal price | 1,579 yen per share |
| (4) Total value of shares to be disposed of | 167,058,200 yen |
| (5) Allottees and number thereof; number of disposed shares | Board of Directors of the Company (excluding Outside Directors): 3 persons / 61,000 shares Corporate Officers who are not the Board of Directors of the Company: 12 persons / 44,800 shares |